glp-1 clinical studies receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Glucagon-like peptide 1 receptor agonists

The evidence summarised in this review is limited and indirectly addresses the reviews research question as many of the studies used artificially induced resistant or susceptible organisms, which may not reflect the mechanisms that develop in field settings

Injectable semaglutide has the longest real-world track record and a well-characterised cardiovascular benefit profile

The convergence of functional medicine principles with cutting-edge pharmaceutical research exemplifies the future of medicine where we address root causes using all available tools, whether natural or pharmaceutical, always keeping the individual patient at the center of care

What looks like success on the scale often reflects a mix of fat loss and lean mass loss